Video

Weighing Safety Risks and Efficacy of New Vitrectomy Procedure Option

Author(s):

As with all new technologies for surgical procedures, there will be questions to be answered about the safety for hypersonic vitrectomy. While human trials have not started yet, there are good indications in cadaveric and animal studies.

As with all new technologies for surgical procedures there will be questions to be answered about the safety for hypersonic vitrectomy. While human trials have not started yet there are good indications in cadaveric and animal studies.

Speaking at the annual meeting of the American Academy of Ophthalmology in Chicago, Paulo E. Stanga, MD, from the Manchester Royal Eye Hospital, said the procedure he has helped develop "is as effective as the commercially available guillotine technology in removing the vitreous." Stanga said if human trials go well the technology should be available to surgeons at some point in 2017.

Related Videos
Aflibercept 8 mg Shows Durability at 3 Years in Wet AMD with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center
Aflibercept 8 mg Noninferior for RVO in QUASAR with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center
Greg A. Sachs, MD I Credit: Regenstrief Institute
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
© 2025 MJH Life Sciences

All rights reserved.